TABLE 3.
Comparison of patients with and without CATE
| In patients with CATE | In patients without CATE | p | |
|---|---|---|---|
| Age | 48.8 | 46.6 | 0.481 |
| Mean BMI | 28.4 | 27.9 | 0.549 |
| Comorbidities | |||
| Hypertension | 40.4% | 23.1% | 0.014* |
| Diabetes mellitus | 22.8% | 15.6% | 0.229 |
| Indicators of COVID‐19 severity | |||
| Rate of hospitalization | 56.1% | 46.9% | 0.238 |
| Presence of fever | 63.2% | 59.9% | 0.665 |
| Peak body temperature (°C) | 38.0 | 38.0 | 0.666 |
| Peak level of CRP | 6.8 | 10.8 | 0.265 |
| Length of hospital stay (days) | 7.0 | 8.6 | 0.083 |
| Duration of COVID‐19 symptoms (days) | 13.8 | 14.2 | 0.924 |
| Mean stress scores (1–10) during infection | 7.7 | 7.1 | 0.171 |
| Usage of drugs during infection | |||
| Favipiravir | 59.6% | 70.1% | 0.155 |
| Antibiotics | 57.9% | 47.6% | 0.188 |
| Enoxaparin | 52.6% | 46.3% | 0.414 |
| Corticosteroids | 40.4% | 35.4% | 0.508 |
| Parasetamol | 33.3% | 35.4% | 0.784 |
| Lopinavir/Ritonavir | 26.3% | 15.0% | 0.059 |
| Acetylsalicylic acid | 12.3% | 23.1% | 0.075 |
| NSAID | 8.8% | 8.8% | 0.987 |
| Hydroxychloroquine | 3.5% | 2.7% | 0.765 |
Abbreviations: BMI, body mass index; CATE, COVID‐19 associated telogen effluvium; CRP, C‐reactive protein; NSAID, non‐steroidal anti‐inflammatory drugs.
*
p < 0.05.